Brian J. Spencer

A brain-shuttled antibody targeting alpha synuclein aggregates for the treatment of synucleinopathies

This paper presents preclinical data on a bispecific antibody, SAR446159, designed to target alpha-synuclein aggregates and cross the blood-brain barrier for treating synucleinopathies.

Anti-Sense Oligonucleotide as a Therapeutic for Synucleinopathies: Pharmacokinetic, Safety and Efficacy Evaluation

This study evaluates an antisense oligonucleotide (ASO) therapy for synucleinopathies, showing effective CNS delivery and reduction of α-synuclein levels in a mouse model.

Transcriptome analyses reveal tau isoform-driven changes in transposable element and gene expression

This study shows tau isoforms alter transposable element and gene expression in neurodegenerative diseases, with locus-specific dysregulation similar to patient samples.

Novel Small Molecules Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein Protect Against Diverse α-Synuclein Mediated Dysfunctions

This study identifies small molecules that target the intrinsically disordered ensemble of α-synuclein, showing they can inhibit misfolding, restore phagocytosis, and block cellular transmission of α-synuclein.